Recent case reports and series have demonstrated the usefulness of ⁶⁸Ga/¹⁸F-PSMA PET/CT in restaging recurrent renal cancer after nephrectomy. We presented a case of a patient with renal mass who had undergone both ¹⁸F-FDG and ⁶⁸Ga-PSMA PET/CT for diagnosis and staging. Concordant tracer uptake in the primary tumor and metastatic lesions was demonstrated by both radiotracers. Final histopathological reports revealed clear cell renal cell carcinoma. Furthermore, unusual left metacarpal bone metastasis was also detected.

1. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:706–720.
2. Spatz S, Tolkach Y, Jung K, et al. Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal Tumors: implications for imaging studies and prognostic role. JUrol. 2018;199:370–377.
3. Chang SS, O'Keefe DS, Bacich DJ, et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res. 1999;5: 2674–2681.
4. Burglin SA, Hess S, Høilund-Carlsen PF, et al. 18F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary: a systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e6713.
5. Evangeslita L, Cuppari L. 18F-FDG or 68Ga/18F-PSMA PET/CT in recurrent renal cell? Clin Transl Imaging. 2018;6:329–330.
6. Sasikumar A, Joy A, Nanabala R, et al. Complimentary pattern of uptake in 18F-FDG PET/CTand 68Ga–prostate-specific membrane antigen PET/CT in a case of metastatic clear cell renal carcinoma. Clin Nucl Med. 2016;41: e517–e519.
7. Hernandez-Cortes P, Caba-Molina M, Gomez-Sanchez R, et al. Renal clear cell carcinoma acrometastasis. An unusual terminal condition. JHandMicrosurg. 2015;7:149–151.
8. Liu Y. The place of FDG PET/CT in renal cell carcinoma: value and limitations. Front Oncol. 2016;6:201.